| Style | Citing Format |
|---|---|
| MLA | Zare M, et al.. "Longitudinal Evaluation of C3- and L3-Derived Skeletal Muscle Indices for Cancer-Specific Survival and Recurrence Endpoints in Radiotherapy-Treated Head and Neck Cancer." Oral Radiology, vol. , no. , 2026, pp. -. |
| APA | Zare M, Mohebbi A, Pak N, Mirghaderi P, Ardakani A A, Mohammadi A (2026). Longitudinal Evaluation of C3- and L3-Derived Skeletal Muscle Indices for Cancer-Specific Survival and Recurrence Endpoints in Radiotherapy-Treated Head and Neck Cancer. Oral Radiology, (), -. |
| Chicago | Zare M, Mohebbi A, Pak N, Mirghaderi P, Ardakani A A, Mohammadi A. "Longitudinal Evaluation of C3- and L3-Derived Skeletal Muscle Indices for Cancer-Specific Survival and Recurrence Endpoints in Radiotherapy-Treated Head and Neck Cancer." Oral Radiology , no. (2026): -. |
| Harvard | Zare M et al. (2026) 'Longitudinal Evaluation of C3- and L3-Derived Skeletal Muscle Indices for Cancer-Specific Survival and Recurrence Endpoints in Radiotherapy-Treated Head and Neck Cancer', Oral Radiology, (), pp. -. |
| Vancouver | Zare M, Mohebbi A, Pak N, Mirghaderi P, Ardakani A A, Mohammadi A. Longitudinal Evaluation of C3- and L3-Derived Skeletal Muscle Indices for Cancer-Specific Survival and Recurrence Endpoints in Radiotherapy-Treated Head and Neck Cancer. Oral Radiology. 2026;():-. |
| BibTex | @article{ author = {Zare M and Mohebbi A and Pak N and Mirghaderi P and Ardakani A A and Mohammadi A}, title = {Longitudinal Evaluation of C3- and L3-Derived Skeletal Muscle Indices for Cancer-Specific Survival and Recurrence Endpoints in Radiotherapy-Treated Head and Neck Cancer}, journal = {Oral Radiology}, volume = {}, number = {}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Zare M AU - Mohebbi A AU - Pak N AU - Mirghaderi P AU - Ardakani A A AU - Mohammadi A TI - Longitudinal Evaluation of C3- and L3-Derived Skeletal Muscle Indices for Cancer-Specific Survival and Recurrence Endpoints in Radiotherapy-Treated Head and Neck Cancer JO - Oral Radiology VL - IS - SP - EP - PY - 2026 ER - |